Nutritional elixirs as third consolidated pillar for NanoRepro

NanoRepro acquires full control of hyped about science to independently develop ALPHABIOL. Adjusting FY26e estimates to € 19m (eNuW) in revenue and € -0.3m (eNuW) in EBITDA. Maintaining BUY at a PT of € 4.4.